New therapeutic targets for the management of moderate-severe psoriasis
Journal of IMIDs · 2022
DOI: 10.24875/jimids.m21000016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of IMIDs, 2022. Verfasst von José C. Ruiz-Carrascosa und 3 weiteren Autor:innen.
Abstract (Originalsprache)
The field of moderate-severe psoriasis is experiencing a real therapeutic revolution in recent years with the appearance of new molecules that present more selective pathophysiological targets.The incorporation of biosimilar drugs with less clinical development than the original brands may result in the incorporation of new molecules with better levels of efficacy and safety being relegated to the background.In the present review, we review the main anti-IL-17, anti-IL-23, and JAKi drugs that have been incorporated and will soon be incorporated into our therapeutic arsenal, making special mention of their efficacy, safety, and persistence characteristics as deduced from the main pivotal clinical trials and series of real clinical practice.
Zitieren
APA
Ruiz-Carrascosa, J. C., Ayén-Rodriguez, A., Llamas-Molina, J. M., & Ruiz-Villaverde, R. (2022). New therapeutic targets for the management of moderate-severe psoriasis. Journal of IMIDs. https://doi.org/10.24875/jimids.m21000016
Vancouver
Ruiz-Carrascosa JC, Ayén-Rodriguez A, Llamas-Molina JM, Ruiz-Villaverde R. New therapeutic targets for the management of moderate-severe psoriasis. Journal of IMIDs. 2022. doi:10.24875/jimids.m21000016
BibTeX
@article{RuizCarrascosa2022,
author = {Ruiz-Carrascosa, José C. and Ayén-Rodriguez, Angela and Llamas-Molina, José M. and Ruiz-Villaverde, Ricardo},
title = {New therapeutic targets for the management of moderate-severe psoriasis},
journal = {Journal of IMIDs},
year = {2022},
doi = {10.24875/jimids.m21000016}
}
EUVIMED